{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:21:28Z","timestamp":1791472888420,"version":"4.3.4"},"reference-count":70,"publisher":"Rockefeller University Press","issue":"3","license":[{"start":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000},"content-version":"vor","delay-in-days":589,"URL":"http:\/\/www.rupress.org\/terms\/"},{"start":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:00:00Z","timestamp":1535932800000},"content-version":"vor","delay-in-days":208,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,3,5]]},"abstract":"<jats:p>Depletion of immunosuppressive tumor-associated macrophages (TAMs) or reprogramming toward a proinflammatory activation state represent different strategies to therapeutically target this abundant myeloid population. In this study, we report that inhibition of colony-stimulating factor-1 receptor (CSF-1R) signaling sensitizes TAMs to profound and rapid reprogramming in the presence of a CD40 agonist before their depletion. Despite the short-lived nature of macrophage hyperactivation, combined CSF-1R+CD40 stimulation of macrophages is sufficient to create a proinflammatory tumor milieu that reinvigorates an effective T cell response in transplanted tumors that are either responsive or insensitive to immune checkpoint blockade. The central role of macrophages in regulating preexisting immunity is substantiated by depletion experiments, transcriptome analysis of ex vivo sorted TAMs, and gene expression profiling of whole tumor lysates at an early treatment time point. This approach enabled the identification of specific combination-induced changes among the pleiotropic activation spectrum of the CD40 agonist. In patients, CD40 expression on human TAMs was detected in mesothelioma and colorectal adenocarcinoma.<\/jats:p>","DOI":"10.1084\/jem.20171440","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T10:25:07Z","timestamp":1518517507000},"page":"859-876","update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":205,"title":["Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity"],"prefix":"10.1084","volume":"215","author":[{"given":"Sabine","family":"Hoves","sequence":"first","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8678-2901","authenticated-orcid":true,"given":"Chia-Huey","family":"Ooi","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany 1"},{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Wolter","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadassah","family":"Sade","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8397-5855","authenticated-orcid":true,"given":"Stefan","family":"Bissinger","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8037-5309","authenticated-orcid":true,"given":"Martina","family":"Schmittnaegel","sequence":"additional","affiliation":[{"name":"Swiss Institute for Experimental Cancer Research, School of Life Sciences, \u00c9cole Polytechnique F\u00e9d\u00e9rale de Lausanne, Lausanne, Switzerland 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3915-5670","authenticated-orcid":true,"given":"Oliver","family":"Ast","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Giusti","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3224-9030","authenticated-orcid":true,"given":"Katharina","family":"Wartha","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0221-6054","authenticated-orcid":true,"given":"Valeria","family":"Runza","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Kienast","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Cannarile","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9540-1442","authenticated-orcid":true,"given":"Hyam","family":"Levitsky","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5465-661X","authenticated-orcid":true,"given":"Solange","family":"Romagnoli","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9128-5459","authenticated-orcid":true,"given":"Michele","family":"De Palma","sequence":"additional","affiliation":[{"name":"Swiss Institute for Experimental Cancer Research, School of Life Sciences, \u00c9cole Polytechnique F\u00e9d\u00e9rale de Lausanne, Lausanne, Switzerland 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"R\u00fcttinger","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1855-8745","authenticated-orcid":true,"given":"Carola H.","family":"Ries","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany 1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"key":"2023072609290724900_bib1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/ncb3371","article-title":"Suppression of microRNA activity amplifies IFN-\u03b3-induced macrophage activation and promotes anti-tumour immunity","volume":"18","author":"Baer","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"2023072609290724900_bib2","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science."},{"key":"2023072609290724900_bib3","doi-asserted-by":"publisher","first-page":"6286","DOI":"10.1158\/1078-0432.CCR-13-1320","article-title":"A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma","volume":"19","author":"Beatty","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"2023072609290724900_bib4","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nat. Immunol."},{"key":"2023072609290724900_bib5","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1084\/jem.20131219","article-title":"Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy","volume":"210","author":"Bouchlaka","year":"2013","journal-title":"J. Exp. Med."},{"key":"2023072609290724900_bib6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.0105-2896.2010.00889.x","article-title":"Orphan granzymes find a home","volume":"235","author":"Bovenschen","year":"2010","journal-title":"Immunol. Rev."},{"key":"2023072609290724900_bib7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4049\/jimmunol.176.1.309","article-title":"Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects","volume":"176","author":"Buhtoiarov","year":"2006","journal-title":"J. Immunol."},{"key":"2023072609290724900_bib8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4049\/jimmunol.1600146","article-title":"CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy","volume":"197","author":"Byrne","year":"2016","journal-title":"J. Immunol."},{"key":"2023072609290724900_bib9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.compmedimag.2015.04.001","article-title":"Group sparsity model for stain unmixing in brightfield multiplex immunohistochemistry images","volume":"46","author":"Chen","year":"2015","journal-title":"Comput. Med. Imaging Graph."},{"key":"2023072609290724900_bib10","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1126\/science.1232227","article-title":"Neutralizing tumor-promoting chronic inflammation: a magic bullet?","volume":"339","author":"Coussens","year":"2013","journal-title":"Science."},{"key":"2023072609290724900_bib11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ccell.2016.05.001","article-title":"Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective Fc\u03b3R Engagement","volume":"29","author":"Dahan","year":"2016","journal-title":"Cancer Cell."},{"key":"2023072609290724900_bib12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature."},{"key":"2023072609290724900_bib13","doi-asserted-by":"publisher","first-page":"e1232222","DOI":"10.1080\/2162402X.2016.1232222","article-title":"Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade","volume":"5","author":"Eissler","year":"2016","journal-title":"OncoImmunology."},{"key":"2023072609290724900_bib14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol. Rev."},{"key":"2023072609290724900_bib15","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.coph.2004.02.008","article-title":"The role of the CD40 pathway in the pathogenesis and treatment of cancer","volume":"4","author":"Eliopoulos","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"2023072609290724900_bib16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1053\/j.seminoncol.2010.09.002","article-title":"Biology and clinical applications of CD40 in cancer treatment","volume":"37","author":"Fonsatti","year":"2010","journal-title":"Semin. Oncol."},{"key":"2023072609290724900_bib17","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"key":"2023072609290724900_bib18","unstructured":"Gentleman, R., and R.Ihaka. 2017. The R Stats Package. Documentation for package \u2018stats\u2019 version 3.5.0. https:\/\/stat.ethz.ch\/R-manual\/R-devel\/library\/stats\/html\/00Index.html"},{"key":"2023072609290724900_bib19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.immuni.2010.05.007","article-title":"Alternative activation of macrophages: mechanism and functions","volume":"32","author":"Gordon","year":"2010","journal-title":"Immunity."},{"key":"2023072609290724900_bib20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev.immunol.16.1.111","article-title":"CD40 and CD154 in cell-mediated immunity","volume":"16","author":"Grewal","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"2023072609290724900_bib21","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1158\/0008-5472.CAN-04-4262","article-title":"Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection","volume":"65","author":"Guiducci","year":"2005","journal-title":"Cancer Res."},{"key":"2023072609290724900_bib22","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1161\/ATVBAHA.116.307592","article-title":"Perivascular Macrophages Limit Permeability","volume":"36","author":"He","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2023072609290724900_bib23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature."},{"key":"2023072609290724900_bib24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2023072609290724900_bib25","doi-asserted-by":"publisher","first-page":"e1151595","DOI":"10.1080\/2162402X.2016.1151595","article-title":"Timing of CSF-1\/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy","volume":"5","author":"Holmgaard","year":"2016","journal-title":"OncoImmunology."},{"key":"2023072609290724900_bib26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","article-title":"Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Immunity."},{"key":"2023072609290724900_bib27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/cei.12396","article-title":"Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection","volume":"178","author":"Jenabian","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"2023072609290724900_bib28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature."},{"key":"2023072609290724900_bib29","first-page":"10","article-title":"Digital multiplexed gene expression analysis using the NanoString nCounter system","volume":"Chapter 25","author":"Kulkarni","year":"2011","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"2023072609290724900_bib30","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1084\/jem.20151764","article-title":"The macrophage IRF8\/IRF1 regulome is required for protection against infections and is associated with chronic inflammation","volume":"213","author":"Langlais","year":"2016","journal-title":"J. Exp. Med."},{"key":"2023072609290724900_bib31","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1126\/science.1206954","article-title":"Inhibitory Fc\u03b3 receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies","volume":"333","author":"Li","year":"2011","journal-title":"Science."},{"key":"2023072609290724900_bib32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1084\/jem.193.6.727","article-title":"Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy","volume":"193","author":"Lin","year":"2001","journal-title":"J. Exp. Med."},{"key":"2023072609290724900_bib33","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1182\/blood-2010-02-266296","article-title":"An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation","volume":"116","author":"MacDonald","year":"2010","journal-title":"Blood."},{"key":"2023072609290724900_bib34","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2023072609290724900_bib35","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ccell.2016.09.009","article-title":"T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells","volume":"30","author":"Marigo","year":"2016","journal-title":"Cancer Cell."},{"key":"2023072609290724900_bib36","doi-asserted-by":"publisher","first-page":"7303","DOI":"10.4049\/jimmunol.177.10.7303","article-title":"Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression","volume":"177","author":"Martinez","year":"2006","journal-title":"J. Immunol."},{"key":"2023072609290724900_bib37","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1182\/blood-2012-06-436212","article-title":"Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences","volume":"121","author":"Martinez","year":"2013","journal-title":"Blood."},{"key":"2023072609290724900_bib38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1158\/0008-5472.CAN-13-1816","article-title":"Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy","volume":"74","author":"Mok","year":"2014","journal-title":"Cancer Res."},{"key":"2023072609290724900_bib39","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nri3470","article-title":"Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks","volume":"13","author":"Murphy","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"2023072609290724900_bib40","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.4049\/jimmunol.161.4.1901","article-title":"Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7","volume":"161","author":"Nakajima","year":"1998","journal-title":"J. Immunol."},{"key":"2023072609290724900_bib41","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171435","article-title":"Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity","author":"Perry","year":"2018","journal-title":"J. Exp. Med."},{"key":"2023072609290724900_bib42","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat. Med."},{"key":"2023072609290724900_bib43","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3109\/08830185.2012.698337","article-title":"T-cell-independent antitumor effects of CD40 ligation","volume":"31","author":"Rakhmilevich","year":"2012","journal-title":"Int. Rev. Immunol."},{"key":"2023072609290724900_bib44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1158\/2326-6066.CIR-13-0152","article-title":"Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer","volume":"2","author":"Richman","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"2023072609290724900_bib45","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell."},{"key":"2023072609290724900_bib46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.coph.2015.05.008","article-title":"CSF-1\/CSF-1R targeting agents in clinical development for cancer therapy","volume":"23","author":"Ries","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"2023072609290724900_bib47","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science."},{"key":"2023072609290724900_bib48","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","article-title":"Macrophages and therapeutic resistance in cancer","volume":"27","author":"Ruffell","year":"2015","journal-title":"Cancer Cell."},{"key":"2023072609290724900_bib49","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","article-title":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells","volume":"26","author":"Ruffell","year":"2014","journal-title":"Cancer Cell."},{"key":"2023072609290724900_bib50","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2326-6066.CIR-13-0067","article-title":"Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer","volume":"2","author":"Sandin","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"2023072609290724900_bib51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/bioinformatics\/btt592","article-title":"gCMAP: user-friendly connectivity mapping with R","volume":"30","author":"Sandmann","year":"2014","journal-title":"Bioinformatics."},{"key":"2023072609290724900_bib52","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.3390\/ijms18112306","article-title":"The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity","volume":"18","author":"Scheu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"2023072609290724900_bib53","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng. Des. Sel."},{"key":"2023072609290724900_bib54","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.semcancer.2012.02.002","article-title":"Differentiation and gene expression profile of tumor-associated macrophages","volume":"22","author":"Schmieder","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"2023072609290724900_bib55","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"2023072609290724900_bib56","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell."},{"key":"2023072609290724900_bib57","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.imbio.2012.01.021","article-title":"The mouse dendritic cell marker CD11c is down-regulated upon cell activation through Toll-like receptor triggering","volume":"218","author":"Singh-Jasuja","year":"2013","journal-title":"Immunobiology."},{"key":"2023072609290724900_bib58","doi-asserted-by":"publisher","first-page":"a021857","DOI":"10.1101\/cshperspect.a021857","article-title":"CSF-1 receptor signaling in myeloid cells","volume":"6","author":"Stanley","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2023072609290724900_bib59","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072609290724900_bib60","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.smim.2009.05.011","article-title":"Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis","volume":"21","author":"Suttles","year":"2009","journal-title":"Semin. Immunol."},{"key":"2023072609290724900_bib61","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1089\/107999002753452755","article-title":"ICSBP\/IRF-8: its regulatory roles in the development of myeloid cells","volume":"22","author":"Tamura","year":"2002","journal-title":"J. Interferon Cytokine Res."},{"key":"2023072609290724900_bib62","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell."},{"key":"2023072609290724900_bib63","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature."},{"key":"2023072609290724900_bib64","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.4049\/jimmunol.168.6.2720","article-title":"T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody","volume":"168","author":"Tutt","year":"2002","journal-title":"J. Immunol."},{"key":"2023072609290724900_bib65","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1158\/2326-6066.CIR-15-0052","article-title":"Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression","volume":"3","author":"van der Sluis","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"2023072609290724900_bib66","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","article-title":"Agonistic CD40 antibodies and cancer therapy","volume":"19","author":"Vonderheide","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"2023072609290724900_bib67","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/978-94-024-0921-5_9","article-title":"Regulation and Immune Function of IL-27","volume":"941","author":"Wang","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"2023072609290724900_bib68","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1158\/2326-6066.CIR-17-0258","article-title":"Combination of CD40 agonism and CSF-1R blockade reconditions tumor-associated macrophages and drives potent antitumor immunity","volume":"5","author":"Wiehagen","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"2023072609290724900_bib69","doi-asserted-by":"publisher","first-page":"e50946","DOI":"10.1371\/journal.pone.0050946","article-title":"Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One."},{"key":"2023072609290724900_bib70","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res."}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/215\/3\/859\/1765198\/jem_20171440.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/215\/3\/859\/1765198\/jem_20171440.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T05:29:51Z","timestamp":1690349391000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/215\/3\/859\/42602\/Rapid-activation-of-tumor-associated-macrophages"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3,5]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20171440","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732656077.793544226","asserted-by":"object"}]},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,7]]}}}